StreetInsider.com News Articles

TD Cowen Reiterates Buy Rating on Senseonics Holdings (SENS)

Mon, 21 Sep 2026 09:55:15 -0400

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $15.00 price target on Senseonics Holdings (NYSE: SENS).

The analyst comments "SENS enters 2H26 with a bevvy of growth levers: ramping U.S. DTC conversions, the Eon Care expansion, growing twiist adoption, and a Europe rebound as control of the commercial org. and revenue timing both act as tailwinds. Meanwhile, bundled-pay mix, manufacturing efficiencies, and full economics are driving gross margin expansion, reinforcing the path toward a self-funded model in the long-term."

For an analyst ratings summary and ratings history on Senseonics Holdings click here. For more ratings news on Senseonics Holdings

Senseonics and Beta Bionics to integrate CGM and insulin systems

Mon, 14 Sep 2026 07:00:37 -0400

Senseonics Holdings (NASDAQ: SENS) announced a partnership with Beta Bionics (NASDAQ: BBNX) to integrate the Eversense 365 continuous glucose monitoring system with the iLet Bionic Pancreas automated insulin delivery system, according to a press release dated Sept. 14, 2026.

The companies plan to complete development of the integrated system in the fourth quarter of 2026, with a commercial launch targeted for the same period, subject to required testing, validation activities, and applicable regulatory requirements.

The Eversense 365 is an implantable sensor that measures glucose levels for up to 365 days and requires fingerstick calibration primarily once per week after day 14. The

Senseonics and Beta Bionics to integrate CGM and insulin systems

Mon, 14 Sep 2026 07:00:37 -0400

The Eversense 365 is an implantable sensor that measures glucose levels for up to 365 days and requires fingerstick calibration primarily once per week after day 14. The

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Mon, 14 Sep 2026 07:00:00 -0400

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients

Brings Eversense 365 to the growing community of iLet Bionic Pancreas users

Plan for commercial launch of the integrated system in Q4 2026

GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world’s first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ: BBNX), a pioneering leader in the development of advanced diabetes

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Mon, 14 Sep 2026 07:00:00 -0400

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients

Brings Eversense 365 to the growing community of iLet Bionic Pancreas users

Plan for commercial launch of the integrated system in Q4 2026

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Mon, 14 Sep 2026 07:00:00 -0400

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients

Brings Eversense 365 to the growing community of iLet Bionic Pancreas users

Plan for commercial launch of the integrated system in Q4 2026

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Mon, 14 Sep 2026 07:00:00 -0400

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients

Brings Eversense 365 to the growing community of iLet Bionic Pancreas users

Plan for commercial launch of the integrated system in Q4 2026

Senseonics To Participate in Upcoming Institutional Investor Conferences

Thu, 10 Sep 2026 08:00:00 -0400

GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences. Details on the Company’s participation appear below:

Lake Street 10^th Annual Big Ideas Growth Conference – September 10, 2026 (New York, NY)
Management will host one-on-one meetings with investors at the Lake Street Capital Markets 10^th Annual Big Ideas Growth Conference on Thursday, September 10^th.

H.C. Wainwright 28^th

Senseonics To Participate in Upcoming Institutional Investor Conferences

Thu, 10 Sep 2026 08:00:00 -0400

GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences. Details on the Company’s participation appear below:

Lake Street 10^th Annual Big Ideas Growth Conference – September 10, 2026 (New York, NY)
Management will host one-on-one meetings with investors at the Lake Street Capital Markets 10^th Annual Big Ideas Growth Conference on Thursday, September 10^th.

H.C. Wainwright 28^th

Form 4 Senseonics Holdings, For: Aug 19 Filed by: ROEDER DOUGLAS A

Thu, 20 Aug 2026 18:25:00 -0400
si-local-file:///var/storage/secattach/20260820/26957386.html

Form 4 Senseonics Holdings, For: Aug 19 Filed by: ROEDER DOUGLAS A

Thu, 20 Aug 2026 18:25:00 -0400
si-local-file:///var/storage/secattach/20260820/26957386.html

Form SCHEDULE 13G Senseonics Holdings, Filed by: Sessa Capital IM, L.P.

Fri, 14 Aug 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260814/26930566.html

Form SCHEDULE 13G Senseonics Holdings, Filed by: Sessa Capital IM, L.P.

Fri, 14 Aug 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260814/26930566.html

Senseonics Holdings (SENS) Misses Q2 EPS by 2c

Thu, 06 Aug 2026 16:37:30 -0400

Senseonics Holdings (NYSE: SENS) reported Q2 EPS of ($0.63), $0.02 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $14.5 million versus the consensus estimate of $13.36 million.
For earnings history and earnings-related data on Senseonics Holdings (SENS) click here.

Form 10-Q Senseonics Holdings, For: Jun 30

Thu, 06 Aug 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260806/26884667.html

Form 10-Q Senseonics Holdings, For: Jun 30

Thu, 06 Aug 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260806/26884667.html

Form 8-K Senseonics Holdings, For: Aug 06

Thu, 06 Aug 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260806/26884179.html

Form 8-K Senseonics Holdings, For: Aug 06

Thu, 06 Aug 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260806/26884179.html

Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Generated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-year
Raising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to 87%
Achieved gross margin of approximately 59% during Q2, and raising full-year gross margin guidance to a range of 58% to 61% from 55% to 58%

GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous

Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Generated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-year
Raising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to 87%
Achieved gross margin of approximately 59% during Q2, and raising full-year gross margin guidance to a range of 58% to 61% from 55% to 58%

GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous

Form SCHEDULE 13G Senseonics Holdings, Filed by: BlackRock, Inc.

Thu, 30 Jul 2026 11:19:00 -0400
si-local-file:///var/storage/secattach/20260730/26841246.html

Form SCHEDULE 13G Senseonics Holdings, Filed by: BlackRock, Inc.

Thu, 30 Jul 2026 11:19:00 -0400
si-local-file:///var/storage/secattach/20260730/26841246.html

Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time

Tue, 21 Jul 2026 08:00:00 -0400

GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.

Management will hold a conference call to review the Company’s second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at

Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time

Tue, 21 Jul 2026 08:00:00 -0400

GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.

Management will hold a conference call to review the Company’s second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at

Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time

Tue, 21 Jul 2026 08:00:00 -0400

GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.

Management will hold a conference call to review the Company’s second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at